Q9H7B4 (SMYD3_HUMAN) Homo sapiens (Human)
Histone-lysine N-methyltransferase SMYD3 UniProtKBInterProSTRINGInteractive Modelling
It is possible new templates exist for this target since these models were created.
Available Structures
34 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Ligands | ||
|---|---|---|---|---|---|---|
| Crystal structure of human SMYD3 in complex with a VEGFR1 peptide |
Heteromer P17948; | 3×ZN; 1×SAH; 4×ACY; | ||||
| Assess | ||||||
| Crystal structure of human SMYD3 in complex with a MAP3K2 peptide |
Heteromer Q9Y2U5; | 3×ZN; 1×SAH; 2×ACY; | ||||
| Assess | ||||||
| Co-crystal Structure of human SMYD3 with a MEKK2 peptide at 2.13A |
Heteromer Q9Y2U5; | 3×ZN; 1×MG; 3×EDO; 1×SAH; | ||||
| Assess | ||||||
| X-RAY STRUCTURE OF SMYD3 IN COMPLEX WITH the benzodiazepine-based probe BAY-6035 | monomer | 1×UZK; 1×SAM; 3×ZN; | ||||
| Assess | ||||||
| X-RAY STRUCTURE OF SMYD3 IN COMPLEX WITH benzodiazepine-type inhibitor compound 15 | monomer | 1×UZT; 1×SAM; 3×ZN; | ||||
| Assess | ||||||
| Crystal structure of SmyD3 in complex with methyltransferase inhibitor sinefungin | monomer | 1×SFG; 6×GOL; 3×ZN; 2×MG; | ||||
| Assess | ||||||
| X-RAY STRUCTURE OF SMYD3 in complex with benzodiazepine-type inhibitor 6 | monomer | 1×UZQ; 3×ZN; 1×SAM; | ||||
| Assess | ||||||
| Co-crystal Structure of human SMYD3 with Isoxazole Amides Inhibitors | monomer | 3×ZN; 2×MG; 1×SAM; 1×O41; | ||||
| Assess | ||||||
| Co-crystal Structure of human SMYD3 with Isoxazole Amides Inhibitors | monomer | 3×ZN; 2×MG; 2×GOL; 1×SAM; 1×O6A; | ||||
| Assess | ||||||
| Co-crystal Structure of human SMYD3 with Isoxazole Amides Inhibitors | monomer | 3×ZN; 2×MG; 1×EDO; 1×SAM; 1×L0J; | ||||
| Assess | ||||||
| SMYD3 in complex with fragment FL01791 | monomer | 1×SAM; 3×ZN; 1×E45; | ||||
| Assess | ||||||
| Crystal Structure of SMYD3 with Potent and Selective Isoxazole Amide Inhibitor 1 | monomer | 3×ZN; 2×MG; 3×GOL; 1×SAH; 1×LUP; | ||||
| Assess | ||||||
| Co-crystal Structure of human SMYD3 with Isoxazole Amides Inhibitors | monomer | 3×ZN; 2×MG; 3×GOL; 1×SAH; 1×LUP; | ||||
| Assess | ||||||
| Crystal structure of SMYD3 with diperodon S enantiomer bound to allosteric site | monomer | 1×SAM; 1×QKT; 3×ZN; 2×ACT; 2×GOL; | ||||
| Assess | ||||||
| SMYD3 in complex with fragment FL08619 | monomer | 1×SAM; 3×ZN; 1×173; | ||||
| Assess | ||||||
| SMYD3 in complex with fragment FL06268 | monomer | 3×ZN; 2×E4I; 1×SAM; | ||||
| Assess | ||||||
| SMYD3 in complex with fragment FL01507 | monomer | 1×SAM; 3×ZN; 1×9W9; 1×GOL; | ||||
| Assess | ||||||
| Co-crystal structure of human SMYD3 with an aza-SAH compound | monomer | 3×ZN; 2×MG; 1×DMS; 1×62X; | ||||
| Assess | ||||||
| Human lysine methyltransferase Smyd3 in complex with AdoHcy (Form I) | monomer | 1×SAH; 3×ZN; | ||||
| Assess | ||||||
| Human lysine methyltransferase Smyd3 in complex with AdoHcy (Form II) | monomer | 3×ZN; 1×SAH; | ||||
| Assess | ||||||
| Crystal structure of SMYD3 with SAM and oxindole compound | monomer | 3×ZN; 1×SAM; 2×4ZW; 1×EDO; | ||||
| Assess | ||||||
| Crystal structure of SET and MYND domain containing 3; Zinc finger MYND domain-containing protein 1 | monomer | 3×ZN; 1×SAM; 8×GOL; | ||||
| Assess | ||||||
| Crystal structure of SMYD3 conjugate with piperidine-based covalent inhibitor EM127 | monomer | 1×SAM; 1×QON; 1×ACT; 3×ZN; | ||||
| Assess | ||||||
| Cocrystal structure of human SMYD3 with inhibitor Sinefungin bound | monomer | 1×SFG; 3×ZN; | ||||
| Assess | ||||||
| Crystal structure of SMYD3 with diperodon R enantiomer bound to allosteric site | monomer | 1×SAM; 3×GOL; 1×POW; 3×ZN; | ||||
| Assess | ||||||
| Crystal structure of SMYD3 with SAM and EPZ028862 | monomer | 3×ZN; 1×SAM; 1×8WD; 1×PEG; 2×DMS; 3×EDO; | ||||
| Assess | ||||||
| human lysine methyltransferase Smyd3 in complex with AdoHcy (Form III) | monomer | 3×ZN; 1×SAH; | ||||
| Assess | ||||||
| Crystal structure of SmyD3 in complex with covalent inhibitor 3 | monomer | 3×ZN; 1×8HF; 1×SAM; | ||||
| Assess | ||||||
| Crystal Structure of Human Histone-Lysine N-methyltransferase SMYD3 in Complex with S-adenosyl-L-me… | monomer | 3×ZN; 1×SAM; | ||||
| Assess | ||||||
| Crystal structure of SmyD3 in complex with covalent inhibitor 4 | monomer | 3×ZN; 1×8W0; 1×SAM; | ||||
| Assess | ||||||
| Crystal structure of SmyD3 in complex with covalent inhibitor 2 | monomer | 1×8HR; 1×SAM; 3×ZN; | ||||
| Assess | ||||||
| Crystal structure of SMYD3 with SAM and EPZ030456 | monomer | 3×ZN; 1×SAM; 1×4ZX; | ||||
| Assess | ||||||
| Crystal structure of SmyD3 in complex with covalent inhibitor 1 | monomer | 1×SAM; 3×ZN; 1×8NR; | ||||
| Assess | ||||||
| Crystal structure of SmyD3 in complex with covalent inhibitor 5 | monomer | 1×A8U; 3×ZN; 1×SAM; | ||||
| Assess | ||||||
1 SWISS-MODEL model
| Template | Oligo-state | QMEANDisCo | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 3mek.1.A | monomer | 0.91 | 3×ZN; 1×SAM; | 99.53 | ||
| Assess | ||||||
2 SWISS-MODEL models built on isoform sequence
| Template | Isoform | Oligo-state | QMEANDisCo | Range | Ligands | Trg-Tpl Seq id (%) |
|---|---|---|---|---|---|---|
| Isoform 2 | 6paf.1.A | monomer | 0.91 | 1×ZN; 1×O6A; | 99.21 | |
| Assess | ||||||
| Isoform 3 | 3ru0.1.A | monomer | 0.91 | 2×ZN; | 100.00 | |
| Assess | ||||||